Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 3 (2006), Issue 6 (June)

1. Variants in the GH-IGF axis confer susceptibility to lung cancer.
   Genome Res, 16(6): 693-701. [Abstract] [Full-text]
2. The cancer and leukemia group B respiratory committee.
   Clin Cancer Res, 12(11): 3581s-8s. [Abstract] [Full-text]
3. Audio-visual biofeedback for respiratory-gated radiotherapy: impact of audio instruction and audio-visual biofeedback on respiratory-gated radiotherapy.
   Int J Radiat Oncol Biol Phys, 65(3): 924-33. [Abstract] [Full-text]
4. Where next for gefitinib in patients with lung cancer?
   Lancet Oncol, 7(6): 499-507. [Abstract] [Full-text]
5. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
   Genes Dev, 20(11): 1496-510. [Abstract] [Full-text]
6. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC).
   Am J Clin Oncol, 29(3): 252-7. [Abstract] [Full-text]
7. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
   Am J Clin Oncol, 29(3): 246-51. [Abstract] [Full-text]
8. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis.
   J Natl Cancer Inst, 98(11): 748-56. [Abstract] [Full-text]
9. Accumulation of chromium and nickel metals in lung tumors from lung cancer patients in Taiwan.
   J Toxicol Environ Health A, 69(14): 1337-44. [Abstract] [Full-text]
10. Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer.
    Int J Cancer, 119(4): 727-34. [Abstract] [Full-text]
11. Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts.
    Int J Cancer, 119(4): 741-4. [Abstract] [Full-text]
12. Evaluation of xeroderma pigmentosum XPA, XPC, XPD, XPF, XPB, XPG and DDB2 genes in familial early-onset lung cancer predisposition.
    Int J Cancer, 119(4): 964-7. [Abstract] [Full-text]
13. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study.
    Int J Cancer, 119(4): 955-60. [Abstract] [Full-text]
14. Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
    Int J Cancer, 119(5): 1028-38. [Abstract] [Full-text]
15. Vascular perfusion of human lung cancer in a rat orthotopic model using dynamic contrast-enhanced magnetic resonance imaging.
    Int J Cancer, 119(2): 365-72. [Abstract] [Full-text]
16. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy.
    Int J Cancer, 119(2): 269-74. [Abstract] [Full-text]
17. The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma.
    Am J Surg, 192(1): 46-51. [Abstract] [Full-text]
18. The "Big Dog" effect: variability assessing the causes of error in diagnoses of patients with lung cancer.
    J Clin Oncol, 24(18): 2808-14. [Abstract] [Full-text]
19. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.
    J Clin Oncol, 24(18): 2800-7. [Abstract] [Full-text]
20. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
    Toxicol Appl Pharmacol, 214(1): 8-15. [Abstract] [Full-text]
21. Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer.
    Hum Pathol, 37(7): 839-44. [Abstract] [Full-text]
22. Effect of silibinin on the growth and progression of primary lung tumors in mice.
    J Natl Cancer Inst, 98(12): 846-55. [Abstract] [Full-text]
23. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    J Natl Cancer Inst, 98(12): 825-38. [Abstract] [Full-text]
24. Impact of geometrical uncertainties on 3D CRT and IMRT dose distributions for lung cancer treatment.
    Int J Radiat Oncol Biol Phys, 65(4): 1260-9. [Abstract] [Full-text]
25. Reporting and analyzing statistical uncertainties in Monte Carlo-based treatment planning.
    Int J Radiat Oncol Biol Phys, 65(4): 1249-59. [Abstract] [Full-text]
26. Radiofrequency ablation of lung malignancies.
    Ann Thorac Surg, 82(1): 365-71. [Abstract] [Full-text]
27. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer.
    Ann Thorac Surg, 82(1): 254-60. [Abstract] [Full-text]
28. Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines.
    Ann Thorac Surg, 82(1): 249-53. [Abstract] [Full-text]
29. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Ann Thorac Surg, 82(1): 243-8. [Abstract] [Full-text]
30. Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients.
    Ann Thorac Surg, 82(1): 237-42. [Abstract] [Full-text]
31. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication?
    Ann Thorac Surg, 82(1): 232-6. [Abstract] [Full-text]
32. Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer.
    Ann Thorac Surg, 82(1): 227-31. [Abstract] [Full-text]
33. Lung cancer staging: a case for a new T definition.
    Ann Thorac Surg, 82(1): 220-6. [Abstract] [Full-text]
34. Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer.
    Ann Thorac Surg, 82(1): 214-8; discussion 219. [Abstract] [Full-text]
35. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1106-11. [Abstract] [Full-text]
36. Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy alone.
    Int J Radiat Oncol Biol Phys, 65(4): 1112-9. [Abstract] [Full-text]
37. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1087-96. [Abstract] [Full-text]
38. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes.
    Int J Radiat Oncol Biol Phys, 65(4): 1097-105. [Abstract] [Full-text]
39. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.
    Int J Radiat Oncol Biol Phys, 65(4): 1075-86. [Abstract] [Full-text]
40. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
    Mol Carcinog, 45(7): 506-17. [Abstract] [Full-text]
41. Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future.
    Expert Opin Biol Ther, 6(7): 709-16. [Abstract] [Full-text]
42. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials.
    Thorax, 61(7): 597-603. [Abstract] [Full-text]
43. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.
    J Clin Oncol, 24(19): 2998-3006. [Abstract] [Full-text]
44. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    J Clin Oncol, 24(19): 2991-7. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.